Meta-analyses have shown a marginally significant prolonged survival time and higher response rates for S-1 therapy compared with 5-FU therapy [ 3 – 5 ] but not for S-1 therapy compared with capecitabine therapy [ 6 – 9 ].
← all excerpts
The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
1
—
—